advertisement
Abstract #6497 Published in IGR 3-2
Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece
Petounis A; Mylopoulos N; Kandarakis A; Andreanos D; Dimitrakoulias NJournal of Glaucoma 2001; 10: 316-324
PURPOSE: To compare the intraocular (IOP) lowering effect of latanoprost with that of dorzolamide when added to timolol. PATIENTS AND METHODS: This randomized, open-label study with two parallel groups was conducted at five centers in Greece. The study enrolled 148 patients with inadequately controlled open-angle or pseudoexfoliative glaucoma (IOP of at least 22 mmHg) or ocular hypertension (IOP of at least 27 mmHg), who were receiving monotherapy with a β-blocker or dual therapy in which one of the agents was a β-blocker. The patients were switched to timolol 0.5% twice daily for two to four weeks (run-in period) before the start of the study (baseline). At baseline, the patients were randomized to receive latanoprost 0.005% once daily or dorzolamide 2% twice daily as add-on therapy to timolol. The IOP was recorded at 9.30 a.m., 12.30 p.m., and 3.30 p.m. at baseline and at three months. Safety was followed throughout the study. RESULTS: The diurnal IOP reduction was significant in both groups (p < 0.001). The mean IOP reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group. The least square estimate of the mean diurnal IOP reduction after three months was -7.06 mmHg in the latanoprost plus timolol group and -4.44 mmHg in the dorzolamide plus timolol group (p < 0.001). Drugs administered in both treatment groups were well tolerated. CONCLUSION: This study clearly showed that the additive diurnal IOP-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol.
Dr A. Petounis, Department of Ophthalmology, Patissia General Hospital, Halkidos 15-19, Athens, Greece. andre_petounis@hotmail.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
